Tag Archives: Mark Breidenbach

Oppenheimer Remains a Buy on Forty Seven Inc (FTSV)

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Forty Seven Inc (FTSV – Research Report) today and set a price target of $35. The company’s shares closed yesterday at $15.91. Breidenbach said: “Wednesday, we met with management to review

Oppenheimer Remains a Buy on Iovance Biotherapeutics Inc (IOVA)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report), with a price target of $25. The company’s shares closed yesterday at $9.38. Breidenbach noted: “Wednesday, we sat down

Oppenheimer Thinks Global Blood Therapeutics’ Stock is Going to Recover

Oppenheimer analyst Mark Breidenbach reiterated a Buy rating on Global Blood Therapeutics (GBT – Research Report) today and set a price target of $82. The company’s shares closed on Friday at $31.54, close to its 52-week low of $30.15. Breidenbach

Oppenheimer Sticks to Its Buy Rating for Forty Seven Inc (FTSV)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Forty Seven Inc (FTSV – Research Report), with a price target of $35. The company’s shares closed on Friday at $18.58, close to its 52-week high

Oppenheimer Maintains a Buy Rating on Forty Seven Inc (FTSV)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Forty Seven Inc (FTSV – Research Report), with a price target of $35. The company’s shares closed yesterday at $13.10. Breidenbach observed: “Tuesday, Forty Seven reported

Oppenheimer Maintains a Buy Rating on Mesoblast Ltd (MESO)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Mesoblast Ltd (MESO – Research Report), with a price target of $15. The company’s shares opened today at $5.97. Breidenbach noted: “Sunday, at the AHA Scientific